NUZ Share Price Performance
AU$0.14
-0.05 (-26.32%)
Price AU$0.14
Share PriceAU$0.14
We Think Neurizon Therapeutics (ASX:NUZ) Needs To Drive Business Growth Carefully
Jun 12
Neurizon Therapeutics Limited Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 2 Fair Values set on narratives written by author
NUZ Community Narratives
There are no narratives available yet.
Recent NUZ News & Updates
Neurizon Therapeutics Limited Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.031
- Gross Margin
- 100.00%
- Net Profit Margin
- -1,079.02%
- Debt/Equity Ratio
- 0%
Neurizon Therapeutics Limited Competitors
Snowflake Analysis
About NUZ
- Founded
- 2000
- Employees
- n/a
- CEO
- WebsiteView website
Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases. The company develops drug discovery intellectual property for the treatment of neurological diseases. Its lead candidate is NUZ-001, a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neurodegenerative diseases. The company was formerly known as PharmAust Limited and changed its name to Neurizon Therapeutics Limited in October 2024. Neurizon Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
Australian Market Performance
- 7 Days: 1.5%
- 3 Months: 5.4%
- 1 Year: 9.2%
- Year to Date: 9.7%
The market has climbed 1.5% in the last 7 days, lead by the Materials sector with a gain of 3.6%. The market is up 9.2% over the last 12 months. Earnings are forecast to grow by 11% annually. Market details ›